First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing

Fetal Diagnosis and Therapy

Volumn 35, Issue 2, 2014, Pages 118-126

  Wright, D ^a   Syngelaki, A ^b,c   Bradbury, I ^d   Akolekar, R ^b,e   Nicolaides, K H ^b,c  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^d Frontier Science   (United Kingdom)

^e MEDWAY MARITIME HOSPITAL   (United Kingdom)

Author keywords

Aneuploidies; Combined test; Ductus venosus pulsatility index for veins; Fetoprotein; First trimester; Nuchal translucency thickness; Placental growth factor; Pregnancy associated plasma protein A; Serum free hCG

Indexed keywords

ALPHA FETOPROTEIN; CHORIONIC GONADOTROPIN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ANEUPLOIDY; ARTICLE; DUCTUS VENOSUS; FEMALE; FETUS; FETUS ECHOGRAPHY; FETUS HEART RATE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRISOMY 13; TRISOMY 18; TRISOMY 21; BLOOD VESSEL PARAMETERS; CONTROLLED STUDY; DUCTUS VENOSUS PULSATILITY INDEX; GENETIC SCREENING; KARYOTYPE; PHENOTYPE; PRENATAL SCREENING; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; UNITED KINGDOM;

ALGORITHMS; CHORIONIC GONADOTROPIN; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 18; DOWN SYNDROME; FEMALE; HEART RATE, FETAL; HUMANS; MATERNAL AGE; NUCHAL TRANSLUCENCY MEASUREMENT; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; TRISOMY;

EID: 84896113111     PISSN: 10153837     EISSN: 14219964     Source Type: Journal    
DOI: 10.1159/000357430     Document Type: Article

References (24)

1. Nicolaides KH: Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn 2011; 31: 7-15.
2. Snijders RJM, Holzgreve W, Cuckle H, Nicolaides KH: Maternal age-specific risks for trisomies at 9-14 weeks' gestation. Prenat Diagn 1994; 14: 543-552. (Pubitemid 24234883)
3. Snijders RJM, Sebire NJ, Cuckle H, Nicolaides KH: Maternal age and gestational age-specific risks for chromosomal defects. Fetal Diagn Ther 1995; 10: 356-367.
4. Kagan KO, Wright D, Valencia C, Maiz N, Nicolaides KH: Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free b-hCG and pregnancy-associated plasma protein-A. Hum Reprod 2008; 23: 1968-1975.
5. Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH: Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation. Fetal Diagn Ther 2012; 31: 87-93.
6. Bredaki FE, Wright D, Matos P, Syngelaki A, Nicolaides KH: First-trimester screening for trisomy 21 using alpha-fetoprotein. Fetal Diagn Ther 2011; 30: 215-218.
7. Maiz N, Wright D, Ferreira AF, Syngelaki A, Nicolaides KH: A mixture model of ductus venosus pulsatility index in screening for aneuploidies at 11-13 weeks' gestation. Fetal Diagn Ther 2012; 31: 221-229.
8. Nicolaides KH, Wright D, Poon LC, Syngelaki A, Gil M: First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol 2013; 42: 41-50.
9. Robinson HP, Fleming JE: A critical evaluation of sonar crown rump length measurements. Br J Obstet Gynaecol 1975; 82: 702-710.
10. Wright D, Spencer K, Kagan K, Torring N, Petersen O, Christou A, Kallikas J, Nicolaides K: First-trimester combined screening for trisomy 21 at 8-13 weeks. Ultrasound Obstet Gynecol 2010; 36: 404-411.
11. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH: A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
12. Wright DE, Bray I: Estimating birth prevalence of Down's syndrome. J Epidemiol Biostat 2000; 5: 89-97.
13. http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition= tcm%3A77-241261.
14. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna, R Foundation for Statistical Computing, 2011. http://www.R-project.org/.
15. Donalson K, Turner S, Morrison L, Liitti P, Nilsson C, Cuckle H: Maternal serum placental growth factor and α-fetoprotein testing in first trimester screening for Down syndrome. Prenat Diagn 2013;33:457-461.
16. Akolekar R, Syngelaki A, Poon L, Wright D, Nicolaides KH: Competing risks model in early screening for preeclampsia by biophysical and biochemical markers. Fetal Diagn Ther 2013; 33: 8-15.
17. Poon LC, Syngelaki A, Akolekar R, Lai J, Nicolaides KH: Combined screening for preeclampsia and small for gestational age at 11-13 weeks. Fetal Diagn Ther 2013; 33: 16-27.
18. Beta J, Bredaki FE, Calvo JR, Akolekar R, Nicolaides KH: Maternal serum α-fetoprotein at 11-13 weeks' gestation in spontaneous early preterm delivery. Fetal Diagn Ther 2011; 30: 88-93.
19. Maiz N, Nicolaides KH: Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications. Fetal Diagn Ther 2010; 28: 65-71.
20. Chelemen T, Syngelaki A, Maiz N, Allan L, Nicolaides KH: Contribution of ductus venosus Doppler in first-trimester screening for major cardiac defects. Fetal Diagn Ther 2011; 29: 127-134.
21. National Screening Committee Policy. Down's Syndrome Screening. Compiled by the National Screening Committee. 2006. http://www.library.nhs.uk/screening.
22. Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH: Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta analysis. Fetal Diagn Ther, in press.
23. Nicolaides KH, Syngelaki A, Poon LC, Gil M, Wright D: First-trimester contingent screening for trisomies 21, 18 and 13 by biomarkers and maternal blood cell-free DNA testing. Fetal Diagn Ther DOI: 10.1159/000356066.
24. Nicolaides KH: Turning the pyramid of prenatal care. Fetal Diagn Ther 2011; 29: 183-196.